Logo image of JNCE

JOUNCE THERAPEUTICS INC (JNCE) Stock Analyst Ratings

NASDAQ:JNCE - Nasdaq - US4811161011 - Common Stock - Currency: USD

1.88  -0.05 (-2.59%)

After market: 1.92 +0.04 (+2.13%)

Buy % Consensus

80

ChartMill assigns a Buy % Consensus number of 80% to JNCE. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 1.65. This target is -12.29% below the current price.
JNCE was analyzed by 13 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about JNCE.
In the previous month the buy percentage consensus was at a similar level.
JNCE was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

JNCE Historical Analyst RatingsJNCE Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -74 -67 -60 -53 -46 -39 -32 -25 -18 -11 -4 5 10

Price Target & Forecast

Price Low Median Mean High 1.881.011.891.652.10 - -46.28% 0.37% -12.29% 11.70%

Related screens

JNCE Current Analyst RatingJNCE Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6
Up and Down Grades
Date Firm Action Rating
2023-02-24 SMBC Nikko Downgrade Outperform -> Neutral
2023-02-23 Raymond James Downgrade Outperform -> Market Perform
2023-01-03 Piper Sandler Maintains Overweight
2022-11-11 Raymond James Downgrade Strong Buy -> Outperform
2022-08-31 Raymond James Maintains Strong Buy
2022-08-05 HC Wainwright & Co. Maintains Buy
2022-05-23 Piper Sandler Maintains Overweight
2022-05-11 Baird Downgrade Outperform -> Neutral
2022-05-06 Raymond James Upgrade Outperform -> Strong Buy
2022-02-04 Cowen & Co. Upgrade Market Perform -> Outperform
2021-11-05 Raymond James Maintains Outperform
2021-09-14 Raymond James Upgrade Market Perform -> Outperform
2021-03-15 Piper Sandler Initiate Overweight